Bacterial vaginosis market seen reaching $5.13 billion by 2030

The bacterial vaginosis market is forecast to grow from $3.62 billion in 2026 to $5.13 billion by 2030, driven by rising STI rates, better diagnostics and expanding women’s health services. North America led the market in 2025, while microbiome-based treatments and rapid molecular testing are expected to shape the next phase of growth.

Why it matters: - The bacterial vaginosis market is expanding as women’s health screening, diagnostics and treatment access improve. - The market is forecast to reach $5.13 billion by 2030, signaling sustained demand for testing and care. - Rising sexually transmitted infection rates are adding urgency because bacterial vaginosis can increase vulnerability to infections such as HIV and chlamydia.

What happened: - The Business Research Company released its Bacterial Vaginosis Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The market is estimated at $3.62 billion in 2026, up from $3.31 billion in 2025. - The report projects a 9.4% CAGR in the historical period and a 9.1% CAGR through 2030. - North America held the largest share of the bacterial vaginosis market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report and the full market report are available online.

The details: - Bacterial vaginosis, or BV, is a vaginal infection caused by an imbalance in the natural bacterial ecosystem. - The condition involves a decline in beneficial lactobacilli and an overgrowth of anaerobic bacteria. - Common symptoms include a fishy odor, thin grayish-white vaginal discharge and discomfort. - Many cases remain symptom-free. - Historical growth has been driven by higher BV prevalence among women, more gynecological healthcare services, wider access to oral and topical antibiotics, more diagnostic laboratory facilities and stronger clinical screening efforts. - Future growth is expected to come from microbiome-based treatments, rapid molecular diagnostic technologies, preventive women’s health initiatives, telehealth diagnosis and investment in alternatives to traditional antibiotic therapies. - Expected market trends include more point-of-care tests, higher demand for targeted antibiotic treatments, greater awareness of vaginal microbiome health, growth in home-based testing and more early detection and screening programs.

Between the lines: - The report ties market growth to a broader shift in women’s health toward earlier diagnosis, faster testing and more personalized treatment options. - Rising STI rates strengthen the commercial case for BV screening because untreated vaginal imbalance can make infections more likely. - The ECDC reported rising STI cases in Sweden, including gonorrhea increasing 31% year over year to 96,969 cases in 2023, syphilis rising 13% to 41,051 cases and chlamydia notifications increasing 3% to 230,199 cases. - North America’s lead suggests the market is being shaped by advanced healthcare infrastructure and stronger investment in women’s health.

What's next: - The market is expected to keep expanding as rapid molecular diagnostics and telehealth become more common in BV care. - Companies and health systems are likely to focus more on preventive screening and alternative therapies that reduce reliance on standard antibiotics. - Point-of-care and home-based testing could gain traction if demand for faster and more accessible diagnosis continues to rise.

The bottom line: - BV is moving from a niche women’s health issue to a larger diagnostic and treatment market with room for steady growth through 2030.